Search Results - strategy

2 Results

Sort By:

A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs

This technology is directed to the discovery of specific microRNAs that target and downregulate enzymes within the cholesterol biosynthetic pathway and is currently being tested in vivo. Briefly, microRNAs regulate the translation of messenger RNAs (mRNAs) into protein. The inventors have discovered a set of specific microRNAs that downregulate the...

Published: 4/8/2024 | Inventor(s): Alan Remaley, Kasey Vickers

Keywords(s): BBXXXX, BIOSYNTHESIS, CHOLESTEROL, ICXXXX, IXXXXX, MicroRNAs, Novel, Patent Category - Biotechnology, REGULATE, STRATEGY

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, Application > Diagnostics, Application > Research Materials

Conditional V2 Vasopressin Receptor Mutant Mice as a Model to Study X-linked Nephrogenic Diabetes Insipidus (XNDI)

X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss of renal urine-concentrating ability. At present, no specific pharmacological therapy has been developed for XNDI, primarily due to the lack of suitable animal models. This technology...

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): ACXXXX, AXXXXX, Chromosome 7, monosomy, Conditional, Deletion 7, DIABETES, Insipidus, Mice, MUTANT, Nephrogenic, Nephrogenic diabetes insipidus, Novel, RECEPTOR, RXXXXX, STRATEGY, Studied, treatment, V2, VASOPRESSIN, X-LINKED

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials